A Study of Letermovir to Prevent a Recurrence of Cytomegalovirus Infection


Full Title

An Open-label, Single-arm Study of Letermovir (LTV) for Prevention of Recurrent CMV Infection in High-risk Hematopoietic Cell Transplant (HCT) Recipients


Cytomegalovirus (CMV) is a potential complication after a stem cell transplant from a donor. It can cause serious infections, due to patients’ recovering immune systems. There are drugs used to treat CMV, but the virus becomes resistant to these drugs in some patients or the patient cannot tolerate the side effects. Even if the infection is initially treated successfully, some patients have a high risk of the infection coming back.

In this study, researchers are exploring the effectiveness of letermovir for preventing CMV infection from coming back after treatment is completed. The side effects of this medication may be less severe than those caused by valganciclovir, ganciclovir, or foscarnet (other CMV drugs). Letermovir stops CMV from reproducing in a different way than these drugs. 

Who Can Join

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have already been treated for CMV following a stem cell transplant from a donor and had a high risk of the infection coming back.
  • This study includes patients age 12 and older.



For more information about this study, please contact the office of Dr. Genovefa Papanicolaou at 212-639-8361.




Phase II (phase 2)


ClinicalTrials.gov ID